1
Clinical Trials associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)
The study will investigate, primarily, the safety, feasibility and tolerability and, secondarily, the preliminary efficacy of an allogeneic bone marrow-derived Mesenchymal Stromal Cell (MSC) therapy (ORBCEL-M) in study subjects with type 2 diabetes (T2D) and progressive diabetic kidney disease (DKD).
100 Clinical Results associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
100 Translational Medicine associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
100 Patents (Medical) associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
100 Deals associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)